Triple
T10790400
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | White Oak, Maryland |
E254561
|
entity |
| Predicate | isNearFederalFacility |
P22439
|
FINISHED |
| Object |
U.S. Food and Drug Administration Office of Pediatric Therapeutics
The U.S. Food and Drug Administration Office of Pediatric Therapeutics is an FDA office dedicated to ensuring that medical products are appropriately studied, labeled, and regulated for safe and effective use in children.
|
E886017
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: U.S. Food and Drug Administration Office of Pediatric Therapeutics | Statement: [White Oak, Maryland, isNearFederalFacility, U.S. Food and Drug Administration Office of Pediatric Therapeutics]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: U.S. Food and Drug Administration Office of Pediatric Therapeutics Context triple: [White Oak, Maryland, isNearFederalFacility, U.S. Food and Drug Administration Office of Pediatric Therapeutics]
-
A.
American Society for Clinical Pharmacology and Therapeutics
The American Society for Clinical Pharmacology and Therapeutics is a professional organization dedicated to advancing the science and practice of clinical pharmacology and translational medicine to improve patient care.
-
B.
Office of Orphan Products Development
The Office of Orphan Products Development is a U.S. Food and Drug Administration office that promotes the development of drugs and other medical products for rare diseases and conditions.
-
C.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
D.
Office of Pharmacy Affairs
The Office of Pharmacy Affairs is a division within the U.S. Health Resources and Services Administration that oversees federal drug discount initiatives for safety-net healthcare providers.
-
E.
Office of Pharmaceutical Quality
The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: U.S. Food and Drug Administration Office of Pediatric Therapeutics Triple: [White Oak, Maryland, isNearFederalFacility, U.S. Food and Drug Administration Office of Pediatric Therapeutics]
Generated description
The U.S. Food and Drug Administration Office of Pediatric Therapeutics is an FDA office dedicated to ensuring that medical products are appropriately studied, labeled, and regulated for safe and effective use in children.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: U.S. Food and Drug Administration Office of Pediatric Therapeutics Target entity description: The U.S. Food and Drug Administration Office of Pediatric Therapeutics is an FDA office dedicated to ensuring that medical products are appropriately studied, labeled, and regulated for safe and effective use in children.
-
A.
American Society for Clinical Pharmacology and Therapeutics
The American Society for Clinical Pharmacology and Therapeutics is a professional organization dedicated to advancing the science and practice of clinical pharmacology and translational medicine to improve patient care.
-
B.
Office of Orphan Products Development
The Office of Orphan Products Development is a U.S. Food and Drug Administration office that promotes the development of drugs and other medical products for rare diseases and conditions.
-
C.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
D.
Office of Pharmacy Affairs
The Office of Pharmacy Affairs is a division within the U.S. Health Resources and Services Administration that oversees federal drug discount initiatives for safety-net healthcare providers.
-
E.
Office of Pharmaceutical Quality
The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d6aa609f008190a294200aefcb7bd5 |
completed | April 8, 2026, 7:20 p.m. |
| NER | Named-entity recognition | batch_69d732f5b8248190a633dc44ae620a3a |
completed | April 9, 2026, 5:02 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69de5637ec50819087f1a0372f89197d |
completed | April 14, 2026, 2:59 p.m. |
| NEDg | Description generation | batch_69de5eadb9448190bdf69711394e2ab7 |
completed | April 14, 2026, 3:35 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69de607917808190922df6521d7bfb07 |
completed | April 14, 2026, 3:42 p.m. |
Created at: April 8, 2026, 9:17 p.m.